- cafead   Oct 12, 2023 at 11:42: AM
via Pfizer is expanding the reach of its BRAF-MEK combo as the pharma giant looks to further build up its oncology presence.
The FDA has approved Pfizer’s Braftovi and Mektovi for treating metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations, the agency said Wednesday.
article source
The FDA has approved Pfizer’s Braftovi and Mektovi for treating metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations, the agency said Wednesday.
article source